Analysis for HUM

📈 Growth & Financial Trajectory

Humana's eight-quarter path shows top-line expansion from roughly $29.4B in 2024Q3 to $40.9B in 2026Q2, a +39% increase. Net income rose from about $0.48B to $0.69B, albeit with volatility including deep troughs of -$0.68B (2024Q4) and -$0.78B (2025Q4). The trend reflects solid revenue momentum but uneven profitability, with earnings per share mirroring the fluctuations. Overall, revenue momentum is compelling while earnings remain cyclical.

💰 Margins & Cash Flow

• Gross margin has been slim and volatile, ranging roughly from -2% to +6% across the period, signaling limited upfront profitability.
• Operating margins have hovered in the low single digits in positive quarters, with occasional dips during negative quarters.
• Cash flow: operating cash flow has been generally positive, including ≈$1.97B CFO in 2026Q2; investing cash flow has been negative in several quarters, reflecting asset investments (e.g., mid-period negative investing cash flows like -$1.473B in 2025Q3 and -$273M in 2026Q2).
• Overall, recurring cash-generation strength supports liquidity despite margin volatility.

🛡️ Balance Sheet & Liquidity

Total assets stand at about $55.28B with liabilities of roughly $36.63B and equity near $18.65B, yielding a liabilities-to-assets ratio around 0.66. Current assets ($38.08B) versus current liabilities ($21.51B) give a healthy working capital position and a current ratio near 1.77x, underscoring solid short-term liquidity. The balance sheet balance remains favorable with positive equity and ongoing cash generation supporting resilience.

⚠️ Key Drivers & Risks

• Drivers: continued growth in managed care demand and payer mix efficiency; ongoing utilization management and scale benefits.
• Risks: earnings volatility from reimbursement dynamics, regulatory/policy shifts, and potential margin compression if cost pressures persist.